secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alzamend Neuro, Inc. (ALZN)
CIK:        0001677077
Form:       8-K
Filed at:   2025-04-25T23:59:59+00:00
Accession:  0001214659-25-006405
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alzamend Neuro stockholders approve reverse stock split and Series C conversion at annual meeting
--------------------------------------------------------------------------------

- Elected eight directors including William B. Horne, Milton C. Ault III, and others with substantial support; broker non-votes of 2,270,160.
- Ratified Haskell & White LLP as independent auditor for fiscal year ending April 30, 2025; 4,255,027 for, 54,999 against.
- Approved conversion of Series C Preferred Stock into common and warrants for up to $5M (less 5% discount); 757,391 for, 142,345 against.
- Approved reverse stock split at ratio between 1:2 and 1:10, board to set exact ratio by April 24, 2026; 3,252,166 for, 1,077,493 against.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1677077/000121465925006405/0001214659-25-006405-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1677077/000121465925006405/i4252528k.htm
  HTML page:      https://secwatch.observer/filing/0001214659-25-006405

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer